Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 10/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | ATM | Q13315 | 3/20 | 0.41 |
| ▸ | PDE4A | P27815 | 3/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | PDE2A | O00408 | 1/20 | 0.41 |
| ▸ | RGS12 | O14924 | 1/20 | 0.41 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.41 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.41 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.41 |
| ▸ | ABCC5 | O15440 | 1/20 | 0.41 |
| ▸ | PDE6D | O43924 | 1/20 | 0.41 |
| ▸ | PDE8A | O60658 | 1/20 | 0.41 |
| ▸ | GMNN | O75496 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3395769 | 0.85 | SLC29A1 (0.54) | SLC29A1KDM4EATMPDE4APDE4B | |
| SCHEMBL141541 | 0.85 | SLC29A1 (0.54) | SLC29A1KDM4EATMPDE4APDE4B | |
| SCHEMBL9565592 | 0.82 | SLC29A1 (0.49) | SLC29A1KDM4EATMPDE4APDE4B | |
| SCHEMBL15065643 | 0.79 | SLC29A1 (0.48) | SLC29A1KDM4EATMPDE4APDE4B | |
| SCHEMBL4077875 | 0.79 | SLC29A1 (0.43) | SLC29A1KDM4EATMPDE4APDE4B | |
| SCHEMBL7446838 | 0.77 | SLC29A1 (0.47) | SLC29A1KDM4EATMPDE4APDE4B | |
| SCHEMBL2456302 | 0.76 | SLC29A1 (0.49) | SLC29A1KDM4EATMPDE4APDE4B | |
| SCHEMBL11564661 | 0.75 | SLC29A1 (0.42) | SLC29A1KDM4EATMPDE4APDE4B | |
| Mopidamol SCHEMBL9440 | 0.74 | SLC29A1 (0.72) | SLC29A1KDM4EATMPDE4APDE4B | |
| Mopidamol SCHEMBL29352335 | 0.74 | SLC29A1 (0.72) | SLC29A1KDM4EATMPDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0108898-B1 | ORAL GALENICAL FORMS OF MOPIDAMOL | Dr. Karl Thomae GmbH (DE) | 1986-08-20 | — | — | EP | claimed |
| EP-0108898-A1 | Oral galenical forms of mopidamol | Dr. Karl Thomae GmbH (DE) | 1984-05-23 | — | — | EP | claimed |
| US-4329346-A | ANTILEKEMIC AGENTS | BOEHRINGER INGELHEIM GMBH (DE) | 1982-05-11 | — | — | US | claimed |
| EP-0014392-B1 | ANTITHROMBOTIC DRUGS COMBINATION AND PROCESS FOR ITS MANUFACTURE | Dr. Karl Thomae GmbH (DE) | 1981-11-04 | — | — | EP | claimed |
| EP-0019586-A1 | Antithrombotic combination formulas | CIBA-GEIGY AG (CH) | 1980-11-26 | — | — | EP | claimed |
| EP-0014392-A1 | Antithrombotic drugs combination and process for its manufacture | Dr. Karl Thomae GmbH (DE) | 1980-08-20 | — | — | EP | claimed |
| US-20150119399-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2015-04-30 | — | — | US | disclosed |
| EP-2804603-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | President and Fellows of Harvard College (US) | 2014-11-26 | — | — | EP | disclosed |
| WO-2013106547-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-07-18 | — | — | WO | disclosed |
| WO-2011067569-A1 | BIODEGRADABLE STENT COMPRISING AN ACID SCAVENGING AGENT | ARTERIUS LIMITED (GB) | 2011-06-09 | — | — | WO | disclosed |
| US-20090326633-A1 | CONTROLLED RELEASE ENDOPROSTHETIC DEVICE | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-12-31 | — | — | US | disclosed |
| US-20080082156-A1 | CONTROLLED RELEASE ENDOPROSTHETIC DEVICE | EISERT WOLFGANG | 2008-04-03 | — | — | US | disclosed |
| US-20080076786-A1 | USE OF RADICAL-SCAVENGING COMPOUNDS FOR TREATMENT AND PREVENTION OF NO-DEPENDENT MICROCIRCULATION DISORDERS | EISERT WOLFGANG | 2008-03-27 | — | — | US | disclosed |
| US-4329346-A | ANTILEKEMIC AGENTS | BOEHRINGER INGELHEIM GMBH (DE) | 1982-05-11 | — | — | US | disclosed |
| EP-0014392-B1 | ANTITHROMBOTIC DRUGS COMBINATION AND PROCESS FOR ITS MANUFACTURE | Dr. Karl Thomae GmbH (DE) | 1981-11-04 | — | — | EP | disclosed |
| US-4285945-A | SYNERGISTIC MIXTURE OF 2,6-BIS/DIETHANOLAMINO/-4-PIPERIDINO-PYRIMIDO/5,4-D/PYRIMIDINE AND SULFINPYRAZONE | SLICHTER SHERRILL J | 1981-08-25 | — | — | US | disclosed |
| US-4285945-A | SYNERGISTIC MIXTURE OF 2,6-BIS/DIETHANOLAMINO/-4-PIPERIDINO-PYRIMIDO/5,4-D/PYRIMIDINE AND SULFINPYRAZONE | SLICHTER SHERRILL J | 1981-08-25 | — | — | US | disclosed |
| EP-0019586-A1 | Antithrombotic combination formulas | CIBA-GEIGY AG (CH) | 1980-11-26 | — | — | EP | disclosed |
| EP-0019586-A1 | Antithrombotic combination formulas | CIBA-GEIGY AG (CH) | 1980-11-26 | — | — | EP | disclosed |
| EP-0014392-A1 | Antithrombotic drugs combination and process for its manufacture | Dr. Karl Thomae GmbH (DE) | 1980-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119399-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | IAPP, GPR119, PCNA | SLC29A1 3229/4885KDM4E 3682/4885ATM 3754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.